Cignarella Andrea, Bolego Chiara, Paoletti Rodolfo
Department of Pharmacological Sciences, University of Milan, Italy.
Cardiovasc Drugs Ther. 2003 Jul;17(4):361-6. doi: 10.1023/a:1027355928799.
Long-and-short term trials with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have demonstrated significant reductions in cardiovascular and cerebrovascular events in patients with and without preexisting heart disease. Beyond improving the lipid profile, statins have additional effects that may contribute to their overall clinical benefit. Statin treatment appears to reduce global risk profile by affecting both novel and established lipid, inflammatory, and morphologic markers including low-density lipoprotein subclasses, lipoprotein (a), markers of endothelial function, inflammatory mediators, intima-media thickening, and coronary calcification. Although statins may be regarded as a rather homogeneous drug class in terms of biological activity, some agents feature unique properties that have beneficial effects on selected important risk matters.
对3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）进行的长期和短期试验表明，在有或无心脏病史的患者中，心血管和脑血管事件均显著减少。除改善血脂谱外，他汀类药物还有其他作用，可能有助于其总体临床获益。他汀类药物治疗似乎通过影响新的和已确定的脂质、炎症及形态学标志物来降低整体风险，这些标志物包括低密度脂蛋白亚类、脂蛋白(a)、内皮功能标志物、炎症介质、内膜中层增厚和冠状动脉钙化。尽管就生物活性而言，他汀类药物可能被视为一类相当同质化的药物，但某些药物具有独特的特性，对特定的重要风险因素具有有益作用。
